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Abstract 
Background: The Australian and New Zealand (ANZ) Massive Transfusion (MT) Registry (MTR) has been established 
to improve the quality of care of patients with critical bleeding (CB) requiring MT (≥ 5 units red blood cells (RBC) over 
4 h). The MTR is providing data to: (1) improve the evidence base for transfusion practice by systematically collecting 
data on transfusion practice and clinical outcomes; (2) monitor variations in practice and provide an opportunity for 
benchmarking, and feedback on practice/blood product use; (3) inform blood supply planning, inventory manage-
ment and development of future clinical trials; and (4) measure and enhance translation of evidence into policy and 
patient blood management guidelines. The MTR commenced in 2011. At each participating site, all eligible patients 
aged ≥18 years with CB from any clinical context receiving MT are included using a waived consent model. Patient 
information and clinical coding, transfusion history, and laboratory test results are extracted for each patient’s hospital 
admission at the episode level.
Results: Thirty-two hospitals have enrolled and 3566 MT patients have been identified across Australia and New 
Zealand between 2011 and 2015. The majority of CB contexts are surgical, followed by trauma and gastrointestinal 
haemorrhage. Validation studies have verified that the definition of MT used in the registry correctly identifies 94 % 
of CB events, and that the median time of transfusion for the majority of fresh products is the ‘product event issue 
time’ from the hospital blood bank plus 20 min. Data linkage between the MTR and mortality databases in Australia 
and New Zealand will allow comparisons of risk-adjusted mortality estimates across different bleeding contexts, and 
between countries. Data extracts will be examined to determine if there are differences in patient outcomes accord-
ing to transfusion practice. The ratios of blood components (e.g. FFP:RBC) used in different types of critical bleeding 
will also be investigated.
Conclusions: The MTR is generating data with the potential to have an impact on management and policy decision-
making in CB and MT and provide benchmarking and monitoring tools for immediate application.
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Background
Blood transfusion is a common hospital procedure and 
may be life-saving. However, it is not without risk. Known 
risks include transfusion-associated infectious diseases, 
haemolytic transfusion reactions, allergic reactions and 
transfusion-related acute lung injury [1]. Other adverse 
outcomes associated with transfusion, albeit from obser-
vational studies, include longer duration of intensive care 
unit (ICU) and hospital admission [2], multi-organ fail-
ure [3] and higher mortality [4].
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Advances in critical care and surgical techniques have 
resulted in more patients with critical bleeding (CB) 
who require large volume blood transfusion support [5]. 
These “massive transfusions” (MT) have variously been 
defined as 10 or more units of red blood cells (RBC) 
transfused in 24 h or the “transfusion of half of one blood 
volume in 4 h, or more than one blood volume in 24 h” 
(adult blood volume is approximately 70 ml/kg) [6]. MT 
are important because the risks of transfusion are ampli-
fied when larger volumes of products are administered 
[7–9]. The consequences of variations in MT practice on 
patient outcomes are unknown. Reported mortality rates 
for patients requiring MT are between 25 and 48 % [10–
14]. Massive transfusion also poses logistical challenges 
for blood services/laboratories/hospitals as CB requiring 
MT is often unpredictable. These challenges relate to the 
need to have blood available—including Group O RhD 
negative RBCs and other blood components such as fresh 
frozen plasma (FFP), cryoprecipitate and platelets.
The evidence base for transfusion practice is incom-
plete, particularly in patients with CB. In 2011, Austral-
ia’s National Blood Authority (NBA) published patient 
blood management (PBM) Guidelines for CB [6] which 
summarised the available evidence and made recom-
mendations for practice where the body of evidence was 
sufficient. Where there was insufficient evidence, “prac-
tice points” were developed though a consensus-based 
process to guide clinical practice. The PBM Guidelines 
identified major evidence gaps including: (1) the role of 
RBC transfusion; (2) dose, timing and ratio of component 
therapies; (3) effect of non-transfusion interventions; 
and (4) impact of blood component therapies on patient 
outcomes as particularly important [6]. Although high 
quality randomised controlled trials have recently been 
published [15–17], practices such as the routine admin-
istration of a 1:1 ratio of RBC to FFP [10, 11, 18–21] and 
greater use of recombinant activated factor VII (rFVIIa) 
are originally derived from the trauma setting without 
randomised controlled trial evidence. They have subse-
quently been extrapolated to non-trauma settings despite 
important differences in the pathophysiology of CB 
events in other settings, especially obstetrics [22]. Cur-
rently, there is no process for the systematic evaluation of 
compliance with the PBM Guidelines. In addition, there 
are major challenges associated with supplying blood 
products across Australia and New Zealand given their 
geographies, and a dearth of information available on 
clinical outcomes associated with blood transfusion.
Clinical quality registries are one of the most effective 
means of monitoring and encouraging uptake of health-
care guidelines [23]. They lead to improved quality of care 
by providing clinicians with credible risk-adjusted out-
come data, enabling them to benchmark their outcomes 
against local and international data [24–26]. Given the 
incomplete evidence base in CB, the need for data on 
practice/blood product use in Australia and New Zea-
land and the current lack of monitoring of variations in 
practice, we established the Massive Transfusion Registry 




The MTR was established to: (1) improve the evidence 
base for transfusion practice by systematically collecting 
data on MT practice and clinical outcomes; (2) moni-
tor variations in practice and provide an opportunity for 
benchmarking, feedback on practice/blood product use, 
quality and safety in hospital practice and accreditation; 
(3) inform blood supply planning, inventory management 
and development of future clinical trials; and (4) measure 
and enhance translation of evidence into policy and PBM 
Guidelines.
Health care systems in Australia and New Zealand
Health care systems in Australia and New Zealand con-
sist of public and private providers, including hospitals, 
primary health care, clinicians, nurses, other health 
professionals, and government and non-government 
organisations [27, 28]. They deliver many services for the 
prevention and treatment of diseases. In both countries, 
government funds public sector health services and pri-
vate health service providers are owned and operated by 
the private sector.
Overview of Australia and New Zealand blood bank 
networks
The blood bank networks in Australia and New Zealand 
consist of several interconnected organisations involved 
in the supply and management of blood and blood prod-
ucts. National blood services providing allogeneic com-
ponents and fractionated plasma products are operated 
by the Australian red cross blood service or New Zealand 
blood service, funded by national governments. There 
are national regulators (e.g. Therapeutic Goods Admin-
istration in Australia and Medsafe in New Zealand) and 
funding is coordinated at a national level (e.g. National 
Blood Authority in Australia). Specialist societies (e.g. 
ANZ society of blood transfusion) and specialist colleges 
(e.g. Royal Australasian College of Physicians) provide 
education and training in clinical and laboratory transfu-
sion practice. Commonwealth serum laboratories (CSL) 
Behring Australia provides plasma fractionation ser-
vices to both countries. Hospital and private pathology 
services operate hospital blood banks for storage, cross-
matching and issue of blood.
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Governance
A steering committee oversees the conduct, development 
and outputs from the registry. The steering committee 
includes practising clinicians (haematologists, intensiv-
ists, emergency physicians, obstetricians, anaesthetists), 
a statistician and representatives from blood sector part-
ner organisations. Terms of reference for the MTR steer-
ing committee, a data access and publications policy and 
a communications plan are in place. Access to aggregate 
data is provided to steering committee members. Each 
party agrees to treat the data in accordance with their 
obligations under their applicable national legislation for 
intellectual property and privacy. External interested par-
ties, including local investigators at participating sites and 
government agencies, submit formal data requests to the 
steering committee for approval prior to being granted 
data access.
Ethics, consent and permissions
Ethical approval to establish the MTR was granted by 
Monash University Human Research Ethics Committee. 
In addition, ethical approval to collect identifiable patient 
level data has been obtained from all 32 participating hos-
pital sites. It was not practical to obtain individual patient 
consent to participate because the cases are unpredicta-
ble, many are emergencies, and there is a high early mor-
tality in CB/MT. Therefore, a waived consent model was 
chosen. The MTR qualifies for the conditions for waived 
consent as outlined in the NHMRC National Statement 
on Ethical Conduct in Human Research on the basis that: 
(1) involvement in the registry carries no more than low 
risk to participants (2) the benefits from the registry jus-
tify any risks of harm associated with not seeking con-
sent (3) it is impracticable to obtain consent (4) there is 
no known or likely reason for thinking that participants 
would not have consented if they had been asked, and (5) 
there is sufficient protection of their privacy and an ade-
quate plan to protect the confidentiality of data. Consent 
waiver was also suitable on the basis that: (1) Australian 
Commission on Safety and Quality in Health Care guide-
lines suggest that complete data must be collected from 
the entire eligible population in order to minimise selec-
tion bias [29], (2) obtaining written consent is impractical 
for many registries [30], and (3) consent wavier improves 
case-capture [26].
The MTR collects unique patient identifiers (medi-
cal record number, full name, date of birth and gender) 
which are used for the sole purpose of data linkage.
Study population
Patients (≥18  years) at participating hospitals are 
included if they receive  ≥5 units RBC within any 4-h 
period of hospital admission [31]. This definition was 
chosen after verification that it optimised case-capture 
[31]. This was necessary because no standard definition 
of MT exists in the international literature and use of 
some definitions may lead to bias. For example, defin-
ing MT as 10 or more units of RBCs in 24  h (10/24  h) 
may exclude trauma patients who die within the first 
24  h (‘survivorship bias’) whereas patients who do not 
require blood early on, but have a high cumulative trans-
fusion requirement over a longer period, may be dispro-
portionately represented (‘catch-up’ bias). These may 
be overcome by the use of time-dependent MT defini-
tions (e.g. ≥5 units RBC in 4 h and ≥6 units RBC in 6 h), 
which focus on acuity of MT requirements during the 
resuscitation period (in the first 2–6 h following injury). 
We performed a validation study to examine the com-
pleteness of capture of CB events using three different 
definitions of MT (5U RBC in 4 h; 6U RBC in 6 h; 10U 
RBC in 24  h) [31]. The most inclusive definition with 
minimal bias was the 5U RBC in 4  h, which captured 
94 % of all CB events and all types of CB events, includ-
ing obstetric haemorrhage. The least inclusive definition 
was the 10U RBC in 24 h with less than 50 % of patients 
identified. Consequently, the registry uses 5U RBC in 4 h 
to define MT.
Given the difficulty of measuring bleeding reliably and 
identifying when CB occurs across many different clinical 
contexts and hospital sites, eligible patients are identified 
using a computer-generated algorithm to query hospital 
blood bank databases to ensure a centralised and sys-
tematic approach. Each hospital created its own queries 
based on the information system specific to the hospital. 
Hospital participation was contingent on hospitals hav-
ing the data informatics capability to run these scripts 
and manage large volumes of transfusion data. Common 
informatics problems encountered were the inability to 
develop or run a script to identify MT patients, inability 
to conform to the data extraction template, and informat-
ics systems which required manual extraction of labora-
tory data.
Data items
MTR data items are extracted for each patient for each 
hospital admission. A hospital admission represents a 
patient’s entire hospital stay and is demarcated by an 
admission date (the date they were admitted to hospi-
tal) and a separation date (the date they were discharged 
from hospital or the date of their death). Some patients 
will also have episodes of care (EOC), which are phases 
of treatment received by a patient within their hospi-
tal admission. An EOC ends when the principal clinical 
intent changes or when a patient formally separates from 
the hospital. There can be more than one EOC within 
one admission.
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The MTR uses existing, electronically stored clinical 
data from hospital information systems. MTR data are 
captured within three packages (see Fig.  1, Table  1): (1) 
Patient demographic and outcome data in conjunction 
with diagnosis and procedure clinical coding from the 
hospital information services (HIS) or patient adminis-
tration system; (2) full transfusion history for a patient’s 
hospital admission including information on all fresh 
blood products, fractionated plasma products, and 
adjunctive therapies. Both Australia and NZ have nation-
ally standardised products for processes like leucodeple-
tion (100 %). Red cells are all whole blood-derived in both 
countries. Platelets are both whole blood or apheresis-
derived, but they are a standardised product in terms of 
manufacturing specifications. Only products transfused 
(not issued then returned unused), are stored within the 
registry; and (3) Laboratory results for the patient’s hos-
pital admission, both pre- and post-MT, from Laboratory 
Information Systems (LIS). Unique patient identifiers, 
required for verification and linkage, are collected in each 
package.
Derived variables
Derived variables are generated within the registry 
using raw data. They are generated automatically for 
speed, accuracy and efficiency. They include the Charl-
son Comorbidity Index (CCI) to estimate disease burden 
[32, 33]; counts of ICD10 diagnosis codes; unique bleed-
ing contexts within an EOC; counts of each transfusion 
product, laboratory tests for each EOC and survival sta-
tus on discharge and 24 h post-MT.
Data management
Requests for data extraction are made retrospectively on 
a quarterly basis from data custodians at participating 
sites. Retrospective recruitment ensures availability of 
all data items at the time of extraction, especially clinical 
coding data. All data extracts from sites are transferred 
via password protected secure file transfer protocol. 
Subsequent data processing involves source file verifica-
tion for file completeness, formatting and layout (Fig. 2). 
Site-specific conversion modules have been created and 
are used to import the data packages. The conversion 
modules mean that hospitals need to extract data in the 
same way each quarter. Data are imported into the data-
base into ‘staging’ and ‘target’ tables which are accessible 
via remote server. These table views provide opportuni-
ties to check for discrepancies and inconsistencies within 
hospital datasets and whether data from all three pack-
ages (HIS, transfusion history and LIS) have been suc-
cessfully linked. Staging table checks include checks to 
ensure that specific rules to clean data have been applied; 
that there has been correct linkage; that mapping of vari-
ous codes from reference or look-up tables built within 
the database has occurred; and that consistent terminol-
ogy and descriptions of variables for all sites have been 
assigned. Target table checks include the application of 
unique constraints to remove any duplicates and generate 
Fig. 1 MTR data sources
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a number of derived variables using the raw cleaned data 
contained within the various tables. Target checks also 
show whether the database has assigned unique internal 
patient identification numbers associated with unique 
episode IDs, which are in turn associated with unique 
HIS, transfusion history and LIS results. Verification 
Table 1 MTR data items
ICU intensive care unit, ICD10 international classification of disease 10, ACHI Australian classification of health interventions, DRG diagnosis-related group, RBC red 
blood cells, rFVIIa recombinant activated factor VIIa, INR international normalised ratio, APTT activated partial thromboplastin time, MCV mean cell volume, MCHC 
mean cell haemoglobin content, ALP alkaline phosphatase, ALT alanine phosphatase, Gamma GT gamma-glutamyl transpeptidase
Health information services Transfusion history Laboratory test results
Facility identifier Facility identifier
Medical record number Medical reference number pO2
Surname, first name Name pCO2
Date of birth Date of birth pH
Gender Gender H Ion concentration
Admission number Product lot number Calculated bicarbonate
Episode of care number Type of product: RBC, platelets, fresh frozen plasma, cryoprecipitate, 
Prothrombinex-VF, fibrinogen concentrate, rFVIIa
Sodium potassium chloride
Episode sequence number Donation number Anion gap
Date of hospital admission Expiry date of product Measured ionised calcium
Time hospital admission Unit ABO Base deficit (or excess)
Date of episode of care admission Only products issued (and not returned) or transfused
Time of episode of care admission Number of units or volume issued INR
Completion date of episode of care Place issued i.e. ward, theatre, ICU Prothrombin time
Completion time of episode of care Date issued APTT
Date of death or discharge Time issued Fibrinogen level
Time of death or discharge The age of the blood issued D-Dimer (if available)
Name of transferring hospital
 Admission type Haemoglobin
 Discharge unit White blood cell count
 Patient status at discharge Platelet count
 Transfer destination Red blood cell count
 Hospital length of stay (hrs) Haematocrit
 ICU length of stay (hrs) MCV
 Ventilation time MCHC
 Primary clinical specialty
 Sequence of diagnoses codes Sodium
 ALL diagnoses ICD-10-AM codes Potassium
 Descriptions of diagnoses codes Chloride
 Qualifier for each ICD-10-AM code Bicarbonate
 Condition onset flag Urea
 ALL procedure ACHI codes creatinine
 Descriptions of procedure codes
 Procedure dates Bilirubin
 Sequence of procedure codes ALP




Positive or negative for bacterial infection
Lactate
Estimated glomerular filtration rate
Blood group and antibody screen
Page 6 of 10Oldroyd et al. BMC Res Notes  (2016) 9:457 
queries in the target server are also run to check for 
orphan data. Following these quality assurance checks 
the data is deployed to the ‘production’ table from which 
data cuts are taken for all reporting and analyses.
Quality assurance
Quality assurance measures are applied to data item 
selection, requests for data items, data coding and data 
entry (Fig. 2). Data items selected are standardised across 
sites and are provided in most cases by personnel trained 
in data management such as business analysts, HIS staff 
or information technology managers. Requests for data 
items are standardised in project protocols. The data 
importing process includes extensive source file checks, 
the application of business rules and verification of suc-
cessful linkage. As data move through the registry to the 
production database, further checks are applied to verify 
that data are moving correctly, linked successfully, derived 




•Request quarterly data extracts
•Transfer via secure file transfer protocol
•Save data extracts
Step 2    
Review Hospital Data
•Check data extracts for completeness, formang & 
layout
•Match to specificaons & previous data extracts
Step 3         
Import Hospital Data Extracts  to Staging Tables
•Request import of a site’s quarterly data via site-
specific conversion modules 
•Data imported to Staging Tables in Staging server
•Generate Medical Record Number Check
Step 4         
Staging Table Checks
•Verify all Data imported, successfully linked and 
business rules applied correctly
Step 6
Target Table Checks
•Verify all Data is correctly moved to target and linked; 
confirm derived variables are correct and internal IDs 
are generated
•Run queries for duplicates or orphan data
Fig. 2 Flowchart of data extraction into the MTR
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Reporting
Hospital Data Reports to participating sites are generated 
bi-annually. They allow benchmarking of practice with 
comparable health services. Here, de-identified individ-
ual site data are presented and compared with national 
and overall MTR data. Data reports are also customised 
for individual sites by clinical bleeding contexts to facili-
tate meaningful comparison and to identify local targets 
for audit or clinical investigation.
External communication consists of a MTR Newsletter 
(for progress reports/updates, upcoming events and pub-
lications of interest), the Transfusion Outcomes Research 
Collaborative (TORC)/MTR website (for project details), 
a TORC Biennial Report (overview of study achieve-
ments), Annual Investigator meetings (strategic planning 
and networking), MTR special interest group meetings 
(for the investigation of specific clinical questions) and 
data reports to partner organisations (project updates to 
funders).
Pilot data
The MTR builds on the Haemostasis Registry (2005–
2010) which collected data on the off-label use of rFVIIa 
in CB from 96 hospitals and included approximately 3500 
patients in Australia and New Zealand [34]. A pilot MTR 
study was undertaken to test the feasibility of collecting 
MT data at six hospitals and verified that much of the 
information required to analyse CB/MT events is already 
collected for other purposes. The pilot MTR developed 
mechanisms to identify MT patients at sites, extract 
relevant data from each source, securely transfer data 
to Monash University, link data from each source, and 
implement a coding framework to co-ordinate the large 
volume of data supplied. Validation studies were under-
taken to test assumptions and methodologies and verify 
the data [31, 35].
Research arising from the MTR
Validation study
A study limitation is that MTR transfusion time is the 
product issue time from the hospital blood bank, which 
will not always be the same as the exact time the patient 
was administered the product. Therefore, a validation 
study was conducted to examine whether hospital ‘time 
of issue’ of blood products from the blood bank is a reli-
able estimate of the ‘time of transfusion’ [35]. Good con-
cordance was found with the median transfusion time 
for the majority of fresh products being ‘product event 
issue time’ from the blood bank plus 20  min (>30  min 
for FFP), which reflected the expected time to transport, 
check and prepare the transfusion. For the purpose of a 
registry, these results support the use of hospital blood 
bank computer records as an appropriate source of blood 
product information for linking with other data sources.
Data linkages
Data linkage between the MTR and the National Death 
Index (NDI) in Australia and the New Zealand Ministry 
of Health mortality data is performed annually to assess 
30- and 90-day mortality. Collaborative linkage pro-
jects with other clinical registries available through the 
Department of Epidemiology and Preventive Medicine, 
Monash University are being explored to provide context 
specific information and additional outcomes. Data link-
age with other clinical registries will allow case–control 
comparisons of in hospital mortality, hospital and ICU 
LOS and ventilation times with matched patients who 
did not receive MT.
Another opportunity that exists is linkage with Blood 
Net, Australia’s national online inventory management 
system. This would allow an exploration of questions 
relating to blood utilisation at the time of MT (including 
the number of group O, RhD negative RBC). Such a link-
age would also allow an examination of blood utilisation 
for MT as a proportion of overall inventory according to 
institution type, geographical location and type of CB/
MT events, and against PBM guidelines.
Supplementary data collection
Specifically designed sub-studies requiring supplemen-
tary data collection are underway. Transfusion nurses or 
transfusion quality/safety officers or other trained staff at 
participating sites collect the supplementary data.
Economic analyses
Health economic data will be collected in order to esti-
mate costs to the health system of CB/MT, as well as 
modelling economic impacts of variation in practice and 
outcome, and estimates of cost savings and patient ben-
efits that could be realised by improved practice. This 
will enable the conduct of cost-effectiveness analyses 
to determine values of different practices and/or thera-
pies, such as the availability of pre-thawed FFP, use of 
tranexamic acid (TXA, an antifibrinolytic agent) and var-
iations in inventory holdings.
Future directions
Further recruitment of regional and rural sites will allow 
comparisons of clinical practices in non-urban settings 
where blood supply and administration practices may 
differ from metropolitan settings. A preliminary com-
parison suggests there are differences in Australian MT 
patients by hospital type (assigned using Australian 
hospital peer groups) [36] (Table  2). Securing ongoing 
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funding is required for the long-term sustainability of the 
registry.
Strengths and limitations
The MTR has developed a critical mass of clinicians, lab-
oratory scientists and other health professions regularly 
discussing issues around MT, including at annual inves-
tigator meetings and seminars. The MTR is an efficient 
and effective use of resources because it is using existing, 
electronically stored hospital data. It is bi-national and 
has representation across Australia and New Zealand 
from metropolitan and regional sites, including the pri-
vate sector. The datasets received from sites are consist-
ent and remove the need for an individual interpretation 
of patient data or selection of patients. The MTR uses an 
internationally recognised coding system for disease clas-
sification (ICD10 diagnosis coding) and for mapping and 
assigning bleeding contexts. A further strength is that the 
MTR offers the possibility of linkage with other registries 
and databases.
Although the registry has broad participation it is not 
yet nationally representative of Australia or New Zealand. 
Currently 15 Australian and 5 New Zealand sites (n = 20; 
63  %) of the possible 32 sites with ethical approval are 
contributing data (Table  3). The three participating pri-
vate hospitals were opportunistically recruited. Greater 
representation from the private sector is needed. One of 
the main limitations of the MTR is that only data existing 
Table 2 Characteristics of Australian MT patients (n = 2451), by type of Australian peer group hospital contributing data 
to the MTR (n = 15) [36]
a Numbers are counts of Australian hospitals contributing data to the MTR
Principal referral 
hospitals
Women’s hospitals Private acute group B 
hospitals
Public acute group A 
hospitals
Public acute group C 
hospitals
n = 9a n = 1a n = 3a n = 1a n = 1a
No. of MT cases (≥5 
units in 4 h); n (%)
2158 (88.0) 15 (0.6) 46 (1.9) 206 (8.4) 26 (1.1)
No. of MT cases (≥10 
units in 24 h); n (%)
911 (42.2) 8 (53.3) 9 (19.6) 83 (40.3) 6 (23.1)
Gender (male); n (%) 1378 (63.9) 0 (0) 19 (41.3) 134 (65.0) 16 (61.5)
Median age (years); [IQR] 63 [48–74] 40 [38–57] 68 [50–78] 69 [54–77] 73 [62–84]
Median hospital length 
of stay (days); [IQR]
18 [9–35] 9 [6–10] 15 [8–22] 12 [7–28] 6 [5–10]
Admitted to ICU; n (%) 1730 (80.2) 0 (0) 43 (93.4) 143 (69.4) 24 (92.3)
Median ICU length of 
stay (hrs.); [IQR]
75 [17–197] 0 (0) 75 [38–143] 48 [0–120] 85 [15–150]
Median ventilation time 
(hrs.); [IQR]
0 [0–52] 0 (0) 0 (0) 19 [0–134] 0 [0–5]
Survival to hospital 
discharge; n (%)
1706 (79.0) 15 (100) 38 (82.6) 160 (77.7) 24 (92.3)
Median RBC units in 
24 h post-MT onset; 
[IQR]
8 [6–12] 9 [6–11] 6 [6–8] 8 [6–11] 6 [6–9]
Median FFP units in 24 h 
post-MT onset; [IQR]
5 [2–10] 4 [4–7] 2 [0–4] 4 [2–7] 1 [0–2]
Median Cryo units in 
24 h post-MT onset; 
[IQR]
2 [0–10] 0 [0–6] 0 [0–6] 4 [0–8] 0 [0–0]
Median Plts units in 24 h 
post-MT onset; [IQR]
1 [0–2] 1[0–1] 0 [0–1] 0 [0–1] 0 [0–0]
Median RBC: FFP ratio 
in 24 h post-MT onset; 
[IQR]
1.5 [1.1–2.0] 1.5 [1.5–2.0] 2 [1.5–3.5] 1.8 [1.5–2.8] 4 [3–6]
Admission type
 Elective n (%) 649 (30.1) 6 (40.0) 44 (95.7) 50 (24.3) 5 (19.2)
 Emergency n (%) 1252 (58.0) 3 (20.0) 2 (4.3) 156 (75.7) 18 (69.2)
 Maternity n (%) 32 (1.5) 6 (40.0) 0 (0) 0 (0) 3 (11.5)
 Unknown n (%) 225 (10.4) 0 (0) 0 (0) 0 (0) 0 (0)
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within hospital systems can be extracted. Therefore data 
collection from the medical record to obtain further 
information, for example on medication history, adverse 
events or use of MT protocols, will be required for spe-
cific sub-studies.
Conclusions
The MTR is generating data with the potential to have an 
impact on management and policy decision-making in 
CB and MT and providing benchmarking and monitor-
ing tools for immediate application.
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